LOGIN
ID
PW
MemberShip
2025-02-07 05:08
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
¡®Global healthcare M&A to recover this year... AI-China¡¯
by
Cha, Jihyun
Jan 15, 2025 05:53am
Artificial intelligence (AI) and China are expected to be the keywords for mergers and acquisitions (M&A) in the global bio and healthcare sector this year. On the 14th, KoreaBIO disclosed a report by global accounting consulting firm Ernst & Young (EY) that contained the prospects above. According to the report, 130 M&A deals were made in
Company
Cholangiocarcinoma¡¤AML targeted anticancer drug 'Tibsovo'
by
Eo, Yun-Ho
Jan 15, 2025 05:53am
'Tibsovo,' a targeted anticancer drug for cholangiocarcinoma and acute myeloid leukemia (AML), is now available for prescription in general hospitals. According to industry sources, Servier's Tibsovo (ivosidenib), a drug targeting the isocitrate Dehydrogenase 1 (IDH-1) gene mutation, has passed the drug committees (DC) of the 'Big 5' tert
Company
Samsung Biologics signs largest CMO deal¡¦KRW 2 Trillion
by
Cha, Jihyun
Jan 15, 2025 05:52am
Samsung Biologics announced on the 14th that it has signed a contract manufacturing organization (CMO) agreement worth USD 1.41 billion (approximately KRW 2.74 trillion) with a Europe-based pharmaceutical company. This is the largest contract in Samsung Biologics' history. It represents 40% of the total order value of KRW 5.4035 trillion
Company
Hanmi leads the prescription market for 7 consecutive years
by
Chon, Seung-Hyun
Jan 15, 2025 05:52am
Hanmi Pharmaceutical has led the domestic outpatient prescription market for 7 consecutive years. The company has solidified its lead in the market fueled by the strong performance of the new combination drugs it developed with its R&D capabilities. Large pharmaceutical companies such as Chong Kun Dang, Daewoong Pharmaceutical, Yuhan Corp, HK In
Policy
Boryung¡¯s Pomalyst generic soon to be released
by
Lee, Tak-Sun
Jan 14, 2025 05:57am
Boryung's multiple myeloma drug Pomalikin Cap may soon be released in Korea¡¯s market. The drug is the first generic version of Pomalyst Cap (pomalidomide, BMS). The risk-sharing agreement (RSA) applied to the original drug, Pomalyst Cap, ended this month, and the insurance price cap of the drug had been adjusted following the reimburseme
Opinion
[Reporter's View] K-Bio's development and human resource
by
Whang, byung-woo
Jan 14, 2025 05:56am
The Korean pharmaceutical and biotech industry (known as 'K-Bio') has grown robustly over the past few years. K-Bio has successfully out-licensed new drug developments, including the In Vitro Diagnostic (IVD), biosimilar, and CDMO, since the Covid-19 pandemic. However, the industry is concerned about sustainability. The key issue is hu
Opinion
[Reporter¡¯s View] Korean drugs go international this year
by
Son, Hyung Min
Jan 14, 2025 05:56am
Last year, new drugs developed by domestic pharmaceutical companies recorded remarkable achievements overseas. Hanmi Pharmaceutical's Rolontis (U.S. brand name Rolvedon) has continued to grow in the U.S. market. Rolontis is a neutropenia treatment developed by Hanmi Pharmaceutical and became the 33rd new domestic drug to be approved in Ko
Company
'Leclaza¡¤Rybrevant comb therapy' wins nod in KOR
by
Son, Hyung Min
Jan 14, 2025 05:56am
The approval of Leclaza plus Rybrevant combination therapy in South Korea has expanded treatment options for patients with non-small cell lung cancer (NSCLC). As Leclaza combination therapy has shown a positive overall survival (OS) result, it is highly likely to be the first-line standard therapy for treating EGFR-positive NSCLC. Accordin
Company
Samsung Bioepis partners with Teva for Soliris biosimilar
by
Cha, Jihyun
Jan 14, 2025 05:56am
Samsung Bioepis announced on the 12th that it has signed a commercialization partnership agreement with the multinational pharmaceutical company Teva Pharmaceutical Industries to launch Epysqli, a biosimilar of the rare disease treatment Soliris (eculizumab), in the U.S. market. Epysqli is the first hematology biosimilar developed by Sam
Company
Will biotech companies continue 'K-Bio' success?
by
Moon, sung-ho
Jan 13, 2025 05:53am
Korean pharmaceutical and biotech companies have successfully outlicensed new drugs in various fields, including cancer, autoimmune disease, and Alzheimer's disease. However, compared to the year before, analysis suggests that the number of out-licensed cases decreased. Despite such a slowdown, companies focusing on global new drug developmen
1
2
3
4
5
6
7
8
9
10
>